User Tools

Site Tools


allergy:drugs:fexofenadine

Fexofenadine

Classification

  • Second-Generation H1 Antihistamine
  • Selective peripheral H1 receptor inverse agonist
  • Active metabolite of terfenadine

Parent class: Histamine & Antihistamines


Mechanism of Action

Fexofenadine selectively blocks peripheral H1 receptors.

Effects:

  • ↓ Histamine-mediated vasodilation
  • ↓ Capillary permeability
  • ↓ Pruritus
  • ↓ Sneezing and rhinorrhea

Key Feature:

  • Minimal penetration of the blood-brain barrier
  • Essentially non-sedating at therapeutic doses

Pharmacologic Background

Fexofenadine is the active metabolite of terfenadine.

Terfenadine was removed from the market due to QT prolongation and torsades risk (CYP3A4 inhibition interactions).

Fexofenadine:

  • Does not significantly prolong QT interval
  • Does not rely on hepatic metabolism for activation

Pharmacokinetics

  • Oral administration
  • Onset: ~1 hour
  • Duration: ~24 hours
  • Primarily eliminated unchanged in feces and urine
  • Minimal hepatic metabolism

Absorption reduced by:

  • Aluminum/magnesium antacids
  • Fruit juices (apple, orange, grapefruit)

Separate dosing from antacids by at least 2 hours.


Indications

Effective for:

  • Sneezing
  • Itching
  • Rhinorrhea

Less effective for:

  • Nasal congestion (intranasal steroids preferred)

Dosing (Adult)

  • 60 mg PO twice daily
  • OR 180 mg PO once daily

Dose adjustment in renal impairment.


Adverse Effects

Generally very well tolerated.

Possible:

  • Headache
  • Mild nausea
  • Rare dizziness

Sedation:

  • Minimal to none
  • Lowest sedation risk among common 2nd-generation H1 blockers

Contraindications / Cautions

  • Renal impairment (dose adjust)
  • Hypersensitivity

Caution:

  • Avoid coadministration with fruit juice
  • Separate from antacids

Drug Interactions

  • Aluminum/magnesium antacids ↓ absorption
  • Fruit juice ↓ bioavailability
  • Minimal CYP interaction
  • No meaningful QT risk at therapeutic doses

Clinical Pearls

  • Least sedating of the second-generation H1 blockers.
  • Preferred in patients requiring full daytime alertness.
  • Safe cardiovascular profile compared to its predecessor (terfenadine).
  • Does not significantly impair cognition or psychomotor function.
  • Not effective for nasal congestion as monotherapy.

Comparison Within Class

Drug Sedation Risk Elimination Unique Feature
Loratadine Very low Hepatic Active metabolite = desloratadine
Cetirizine Low Renal Slightly more sedating
Levocetirizine Low Renal R-enantiomer refinement
Fexofenadine Minimal Renal/Fecal Least sedating; safe QT profile

allergy/drugs/fexofenadine.txt · Last modified: by andrew2393cns